Welcome to the Oncology Brothers podcast! In this episode, we kick off a three-part CME series focused on small cell lung cancer (SCLC). Joined by Dr. Hossein Borghaei, Chief of Thoracic Oncology at the Fox Chase Cancer Center. Together they dived into the evolving treatment landscape for SCLC, highlighting recent advancements and data from ASCO 2025.

Episode Highlights:

Join us as we navigate the complexities of SCLC treatment and look forward to future advancements that may improve patient outcomes.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

Link to gain CME credits from this activity:

Follow us on social media:

#OncologyBrothers #SmallCellLungCancer #CME #ASCO2025 #LungCancer #Immunotherapy #CancerTreatment

In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC).

Key Topics:

Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations. 

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!

Welcome to the Oncology Brothers podcast! In this episode, we continue our hematology series by diving deep into myelofibrosis (MF) with Dr. Raajit Rampal, an expert in myeloproliferative neoplasms from the Memorial Sloan Kettering Cancer Center.

Join Drs. Rahul and Rohit Gosain as they discuss the latest updates in symptom management, emerging treatment combinations, and the importance of timely diagnosis and risk stratification for patients presenting with cytopenias and splenomegaly.

Key topics covered in this episode include:

Tune in to gain valuable insights into the evolving treatment landscape for myelofibrosis and learn how community oncologists can effectively manage this complex disease.

Follow us on social media:

Don't forget to subscribe for more episodes in our hematology series and check out our previous discussions!

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC).

Episode Highlights:

Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC. 

Follow us on social media:

Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dived deep into the world of myeloproliferative neoplasms (MPNs), focusing specifically on polycythemia vera (PV) and essential thrombocythemia (ET). They are joined by Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, who shared his expertise on the latest treatment paradigms and risk stratification strategies for these conditions.

Key topics discussed included:

Join us for an informative discussion that highlights the evolving landscape of MPN management and the importance of individualized treatment plans. 

Follow us on social media:

Don't forget to check out our other hematology episodes for more insights into challenging cases and treatment algorithms!

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain, practicing community oncologists, share their key takeaways from a session on NTRK Fusion Positive Solid Malignancies, they moderated during a satellite event at ASCO 2025 in partnership with Medscape Global Oncology.

Join us as we discuss:

Don't forget to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit. 

https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679 

Follow us on social media:

#entrectinib #larotrectinib #repotrectinib

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the complexities of relapsed refractory Acute Myeloid Leukemia (AML) with FLT3 mutations. Joined by leukemia specialists Dr. Uma Borate from the Ohio State University and Dr. Naval Daver from the MD Anderson Cancer Center, the discussion focused on real-life cases and the current standard of care for patients with FLT3-positive AML.

Key topics included:

Whether you're a healthcare professional or someone interested in the latest advancements in cancer care, this episode provides valuable insights into the management of challenging AML cases.

Follow us on social media:

Don't forget to subscribe for more discussions on the latest in oncology!

In this episode of The Oncology Brothers, Drs. Rahul and Rohit Gosain are joined by Dr. Anand Patel, a hematologist and Medical Director of Inpatient Leukemia Service at the University of Chicago. Together, they delved into the complexities of acute myeloid leukemia (AML), one of the most aggressive cancers encountered in clinical practice.

Episode Highlights:

Follow us on social media:

YouTube: https://youtu.be/gbgRbrjHxmQ

Join us as we bridge the gap between academic research and community practice, providing valuable insights for healthcare professionals treating AML patients. 

Don't forget to like, subscribe, and check out our other episodes for more discussions on challenging cases and treatment algorithms!

Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases.

In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab.

Key topics covered included:

We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels.

YouTube: https://youtu.be/05ieIyAIx_8

Follow us on social media:

Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain dive deep into the world of diffuse large B-cell lymphoma (DLBCL), one of the most aggressive yet potentially curable lymphomas. We are joined by Dr. John Leonard, a renowned lymphoma expert from NYU Langone Cancer Center, who shares his insights on the latest data and evolving treatment landscape for DLBCL.

Episode Highlights:

YouTube: https://youtu.be/raGkPnUs9XM

Follow us on social media:

Join us as we unpack the complexities of DLBCL treatment and share valuable clinical pearls for community settings. Don't forget to subscribe for more episodes on challenging cases and the latest in oncology!